Tracking the Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tracking the Supply Chain
As the battle against counterfeits gains momentum, PharmTech speaks to Mark Davison, CEO of Blue Sphere Health, and Craig Stobie, global life sciences sector manager at Domino Printing Sciences, about the challenges involved with coding and tracking drugs through the global supply chain. Potential solutions are discussed, including fingerprinting technologies and end-user verification.


Pharmaceutical Technology
Volume 36, Issue 12

PharmTech: In your opinion, how successful has the industry been in fighting drug counterfeiting over the past few years? How would you describe the prevalence of the problem today?

Davison: The situation is totally different depending on where in the world you look. In the EU and US, one would be unlucky to come across a counterfeit medicine. However, as the recent Avastin case (1) showed, even these relatively well-controlled supply chains are vulnerable. In many developing countries, counterfeit drugs constitute a lethal epidemic that is killing thousands of people every year. Most fake drugs are ineffective rather than toxic, and patients still die needlessly from a disease that modern medicine could cure or control because they are taking counterfeits unknowingly. There are no easy answers but there are more things that we could do to help. We need to help these countries to build regulatory capacity, invest in monitoring equipment, educate and involve the end user in the verification process.

Stobie: The problem seems to becoming more prevalent because anticipating where counterfeiting will hit, both geographically and in terms of brand and medicine area, adds to the difficulty. Some have the view that big pharmaceutical companies are more concerned with developing new products and dealing with regulatory issues, and thus, their supply chains are being overlooked. The struggle to encourage a balanced investment in both drug development and supply-chain management can also escalate the problem of counterfeiting.

PharmTech: The globalisation of pharmaceutical supply and manufacturing has contributed to the rise in counterfeit medicines. What are some best practices that the industry can apply to secure their supply chains, especially for products coming from emerging markets such as China and India?

Davison: The key is to examine processes first and then look at security technologies. At Blue Sphere, we use a simple mnemonic called DRASTIC: Define goals, do a Reality check, collate and Analyse data, draw up a Strategy, develop Tactics, plan Implementation, ensure Communication. Many companies make the mistake of jumping to tactics and then getting hung up on technology choice and pack features. Technology bolted on to insecure processes does not add anything except cost. Look at all of your supply chain processes from a counterfeiter’s viewpoint. The right question is not ‘could a criminal copy what we do?’ but ‘could they disrupt, negate, or subvert our processes so that counterfeiting is made possible?’ As a minimum, you should audit all your suppliers for their security processes, as well as the usual product quality parameters. When you are ready to add security features, there are often many free or low cost approaches that you can take. Seek advice and always have a backup plan. Even the best security approaches will eventually be compromised so planned upgrades are a good idea.

Stobie: There are several practices the industry can apply to secure its supply chains. The key ones are:


    ADVERTISEMENT

    blog comments powered by Disqus
    LCGC E-mail Newsletters

    Subscribe: Click to learn more about the newsletter
    | Weekly
    | Monthly
    |Monthly
    | Weekly

    Survey
    How does your company apply quality-by-design (QbD) principles to manufacturing processes?
    To all processes for both new and legacy products
    To all process for new products only
    To select process for new products only
    To select processes for both new and legacy products
    Do not use QbD
    To all processes for both new and legacy products
    18%
    To all process for new products only
    13%
    To select process for new products only
    22%
    To select processes for both new and legacy products
    22%
    Do not use QbD
    24%
    View Results
    UPCOMING CONFERENCES

    Programs for Investigational and Pre-Launch Drugs
    Philadelphia, PA
    July 17-18, 2013
    Request Brochure

    Strategic Pipeline Planning & Portfolio Valuation
    Philadelphia, PA
    August 13-14, 2013
    Request Brochure

    MES 2013 - Forum on Manufacturing Execution Systems
    Philadelphia, PA
    August 14-15, 2013
    Request Brochure

    Mobile Innovation for the Life Sciences Industry
    Philadelphia, PA
    August 20-21, 2013
    Request Brochure

    See All Conferences >>

    Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
    Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
    Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
    Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
     More
    Inadequate Access to Medicines Puts EU at Risk
    FDA Offers Insight on QbD for Modified-Release Products
    Global Biosimilars Market to Reach $2.445 Billion in 2013
    Adapting to Change
    AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
    FindPharma Custom Search
    Source: Pharmaceutical Technology,
    Click here